Clinical Trials Sponsored by CTI BioPharma

Total 2441 results

CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
CTI BioPharma

Completed

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (RAPID)

Diffuse Large-Cell Lymphoma

United States, Germany, Canada, Italy, France
CTI BioPharma

Completed

Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer

Colorectal Cancer

Italy
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
CTI BioPharma

Terminated

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Prostate Cancer

United States
CTI BioPharma

Withdrawn

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NSCLC

United States
CTI BioPharma

Withdrawn

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Non-Hodgkin's Lymphoma

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade

United States
CTI BioPharma

Completed

Phase II CT-2103/Carboplatin in Ovarian Cancer

Ovarian Neoplasm

United States
CTI BioPharma

Withdrawn

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (Hepatic)

Metastatic Cancer

United States
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
CTI BioPharma

Completed

CT-2106 for the Second Line Treatment of Ovarian Cancer

Ovarian Cancer

France, United Kingdom, Italy
CTI BioPharma
Covance

Completed

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Healthy Subjects

United States
CTI BioPharma
Covance

Completed

Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

Healthy Subjects

United States
CTI BioPharma
Covance

Completed

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

Drug Interaction Study

United States
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States
CTI BioPharma
PPD

Completed

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Drug Interactions

United States
CTI BioPharma
Covance

Completed

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Healthy

United States
CTI BioPharma
Covance

Completed

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Healthy Subjects

United States
CTI BioPharma
Chroma Therapeutics

Completed

Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects (8265134)

Healthy

United States
CTI BioPharma
QPS-Qualitix

Completed

Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib

Healthy

Netherlands
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Spain, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
CTI BioPharma
SGS S.A.

Completed

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

Myelofibrosis

Moldova, Republic of, Germany
CTI BioPharma
SGS S.A.

Completed

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

Myelofibrosis

Moldova, Republic of, Germany, Romania
Spectrum Pharmaceuticals, Inc
CTI BioPharma

Terminated

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular | Follicular Lymphoma

United States
Northwestern University
CTI BioPharma; Cephalon

Unknown

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

Brain and Central Nervous System Tumors

United States
Stanford University
CTI BioPharma; Cephalon

Completed

Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma

Brain Cancer

United States
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Leukemia

United States
University of Southern California
CTI BioPharma

Withdrawn

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

Breast Cancer

United States
Dartmouth-Hitchcock Medical Center
CTI BioPharma

Completed

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)

Advanced Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
CTI BioPharma

Completed

CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer

United States
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
CTI BioPharma

Completed

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

Multiple Myeloma | Stem Cell Transplantation

United States
SCRI Development Innovations, LLC
CTI BioPharma

Completed

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
SCRI Development Innovations, LLC
CTI BioPharma

Completed

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Multiple Myeloma
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States

Clinical Trials Sponsored by CTI BioPharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations